Personalis, Inc.
PSNLHealthcareNASDAQDiagnostics & Research · Last scanned Jun 3, 2026
Scan Results
Daily timeframePersonalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. At a $1.17B market cap, Personalis, Inc. ranks as a small-cap company within healthcare. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Market Cap
$1.17B
Beta
1.97
P/E (TTM)
—
P/E (Fwd)
-12.44
EPS (TTM)
$-1.02
EPS (Fwd)
$-0.90
ROE
-41.4%
ROA
-21.4%
Cash
$233.2M
Total Debt
$38.8M
Free CF
-$42.4M
52W Change
116.3%
Annual Financials
Cash vs Debt
With $233.2M in cash and $38.8M in debt, PSNL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$42.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -41.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $65.0M (2022) to $69.6M (2025).
Personalis, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PSNL.